These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24324728)

  • 21. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy.
    Manders P; Bult P; Sweep CG; Tjan-Heijnen VC; Beex LV
    Breast Cancer Res Treat; 2003 Jan; 77(1):77-84. PubMed ID: 12602906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years.
    Janssen EA; Søiland H; Skaland I; Gudlaugson E; Kjellevold KH; Nysted A; Søreide JA; Baak JP
    Cell Oncol; 2007; 29(1):25-35. PubMed ID: 17429139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
    Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
    Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA
    J Clin Oncol; 2005 Sep; 23(25):5993-6001. PubMed ID: 16135467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic utility of atypical mitoses in patients with breast cancer: A comparative study with Ki67 and phosphohistone H3.
    Ohashi R; Namimatsu S; Sakatani T; Naito Z; Takei H; Shimizu A
    J Surg Oncol; 2018 Sep; 118(3):557-567. PubMed ID: 30098295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
    Jonsdottir K; Assmus J; Slewa A; Gudlaugsson E; Skaland I; Baak JP; Janssen EA
    PLoS One; 2014; 9(3):e90642. PubMed ID: 24599057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.
    Baak JP; Gudlaugsson E; Skaland I; Guo LH; Klos J; Lende TH; Søiland H; Janssen EA; Zur Hausen A
    Breast Cancer Res Treat; 2009 May; 115(2):241-54. PubMed ID: 18665447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?
    Feng W; Malpica A; Skaland I; Gudlaugsson E; Robboy SJ; Dalen I; Hua K; Zhou X; Baak JP
    PLoS One; 2013; 8(10):e75899. PubMed ID: 24146786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
    Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.
    Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
    Breast Cancer Res Treat; 2009 Mar; 114(1):39-45. PubMed ID: 18373192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.
    Sicking I; Edlund K; Wesbuer E; Weyer V; Battista MJ; Lebrecht A; Solbach C; Grinberg M; Lotz J; Hoffmann G; Rahnenführer J; Hengstler JG; Schmidt M
    PLoS One; 2014; 9(10):e111306. PubMed ID: 25340395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
    Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
    J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study.
    Lundgren C; Ahlin C; Holmberg L; Amini RM; Fjällskog ML; Blomqvist C
    Acta Oncol; 2015 Apr; 54(4):538-44. PubMed ID: 25327158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.